Lucero
Lucero Bio enables scalable 3D cell culture for preclinical drug development, combining microbiology, artificial intelligence, and microfluidics as a bioconvergence company to deliver more accurate, efficient, and advanced biomedical research solutions.
About Lucero
Founded in 2020, Lucero is a bioconvergence company integrating microbiology, AI and microfluidics to advance modern research. Its technology addresses major challenges in 3D cell-culture handling, miniaturization, and assay preparation, enabling precise, scalable, and automated experimentation that accelerates next-generation biomedical innovation.



